Current Weather
The Spy FM

Patent Ruling In India Could Boost Exports Of Cheap Medicine To Third World

Filed by KOSU News in World News.
April 1, 2013

A decision by India’s Supreme Court to reject Novartis AG’s bid to patent a version of one cancer drug could lead to more exports of cheap medicine from that country to “poor people across the developing world,” the BBC writes.

NPR’s Julie McCarthy tells our Newscast Desk that the ruling, announced Monday, ends a six-year legal battle that has been closely watched by pharmaceutical firms, humanitarian aid organizations and generic drug manufacturers.

She adds that:

“The case highlights the cost difference between foreign pharmaceutical firms looking to protect their investments and local generic competitors copying and selling drugs for a fraction of their original cost. Novartis’ drug, known as Glivec, was a breakthrough treatment in the 1990s for leukemia. It costs about $2,500 a month. The generic version: a couple hundred dollars. When the Swiss drug-maker sought a new patent, Indian officials said it was not changed enough to qualify as a new drug.”

Novartis, as The Associated Press reports, “has previously said that patent protection is crucial to fostering new drug research and innovation and has suggested that Indians could be denied access to its new medicines if it believes its patents won’t be protected.”

Indian authorities, though, ruled that in this case Novartis was applying for protection of a drug that was not substantially different than an earlier version. Under Indian law, companies are prevented from getting new patents if they make only minor changes to an existing medicine — a practice known as “evergreening,” the AP adds.

Brook Baker, a law professor at Northeastern University, “said he doubts the pharmaceutical industry will pull back much on its investments in India based on the decision,” Bloomberg News writes. “The country will still grant 20 year patents on new, innovative drugs and a growing middle class with chronic diseases will provide many business opportunities, he said.”

And The Wall Street Journal adds in a paywall-protected story that “Gopal Dabade of All India Drug Action Network, an India-based non-profit group that works for access to essential medicines, said the ruling will allow Indian generic manufacturers to continue to supply Indians and consumers in other developing countries with cheap medicines.”

Related post from Marketplace Health Care: “India Novartis patent ruling: Good for access, bad for innovation?” [Copyright 2013 NPR]

Leave a Reply

7PM to 9PM Millions Now Listening Will Never Die

Millions Now Listening Will Never Die

Our post-punk show, Millions Now Listening Will Never Die, is hosted by the legendary Jon Mooneyham. Jon is also an adjunct teacher at the Academy of Contemporary Music at the University of Central Oklahoma. He played guitar in the Flaming Lips back in the day and has met and interviewed practically every band alive.

Listen Live Now!

9PM to 5AM The Spy

The Spy

An eclectic mix of the Spy's library of more than 10,000 songs curated by Ferris O'Brien.

View the program guide!

Upcoming Events in your area (Submit your event today!)

Streaming audio and podcasts

Stream KOSU on your smartphone

Phone Streaming

SmartPhone listening options on this page are intended for many iPhones, Blackberries, etc. with low-cost software applications available to listen to our full-time web streams, both News on KOSU-1 and Classical on KOSU-2.

Learn more about our complete range of streaming services

We're perfecting the patient experience - Stillwater Medical Center